Literature DB >> 4139290

Sarcoma and helper-specific RNA tumor virus subunits in transformed nonproducer mouse cells activated to produce virus by treatment with bromodeoxyuridine.

N Tsuchida, M S Shih, R V Gilden, M Hatanaka.   

Abstract

A tumor line (58-2T) was established from a slowly growing tumor in a BALB/c mouse inoculated with M58-2 cells. The latter clonal cell line was isolated after bromodeoxyuridine treatment as a flat variant from nonproducer BALB/3T3 cells transformed by the Kirsten sarcoma virus. The 58-2T cells produced type C virus with two discrete virus-specific RNA species. One of the species, which was probably an endogenous virus RNA subunit, had a sedimentation coefficient of 35S as the largest major subunit, and had sequences similar to Rauscher leukemia virus RNA based on nucleic acid hybridization. The other RNA species had 30S as the largest major subunit and corresponded to Kirsten sarcoma virus-specific RNA. These two RNA species formed heterogeneous, 60 to 70S, high-molecular-weight RNA in virions.DNA transcripts (58-2T DNA) from the activated virus contained base sequences complementary to Rauscher leukemia virus and Kirsten sarcoma virus. The Kirsten sarcoma virus-specific DNA sequences (58-2TS) were purified from 58-2T DNA by eliminating RLV-specific sequences.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4139290      PMCID: PMC355643     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Biochemical studies on adenovirus multiplication. 1. Stimulation of phosphorus incorporation into deoxyribonucleic acid and ribouncleic acid.

Authors:  M GREEN
Journal:  Virology       Date:  1959-11       Impact factor: 3.616

2.  Homology between type-C viruses of various species as determined by molecular hybridization.

Authors:  R E Benveniste; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

3.  Chemical induction of focus-forming virus from nonproducer cells transformed by murine sarcoma virus.

Authors:  S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-12       Impact factor: 11.205

4.  RNA in mammalian sarcoma virus transformed nonproducer cells homologous to murine leukemia virus RNA.

Authors:  R E Benveniste; E M Scolnick
Journal:  Virology       Date:  1973-02       Impact factor: 3.616

5.  Intracellular and virion 35 S RNA species of murine sarcoma and leukemia viruses.

Authors:  N Tsuchida; M Green
Journal:  Virology       Date:  1974-05       Impact factor: 3.616

6.  Infection of an established mouse bone marrow cell line (JLS-V9) with Rauscher and Moloney murine leukemia viruses.

Authors:  B S Wright; P A O'Brien; G P Shibley; S A Mayyasi; J C Lasfargues
Journal:  Cancer Res       Date:  1967-09       Impact factor: 12.701

7.  Ribonucleic acid components of murine sarcoma and leukemia viruses.

Authors:  J Maisel; V Klement; M M Lai; W Ostertag; P Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

8.  Specificity of the DNA product of RNA-dependent DNA polymerase in type C viruses. II. Quantitative analysis.

Authors:  H Okabe; R V Gilden; M Hatanaka
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

9.  Studies on the nucleic acid sequences of Kirsten sarcoma virus: a model for formation of a mammalian RNA-containing sarcoma virus.

Authors:  E M Scolnick; E Rands; D Williams; W P Parks
Journal:  J Virol       Date:  1973-09       Impact factor: 5.103

10.  Mutants of nonproducer cell lines transformed by murine sarcoma virus. II. Relationship of tumorigenicity to presence of viral markers and rescuable sarcoma genome.

Authors:  M Hatanaka; R Klein; C W Lomg; R Gilden
Journal:  J Exp Med       Date:  1973-08-01       Impact factor: 14.307

View more
  12 in total

1.  Base sequence differences between the RNA components of Harvey sarcoma virus.

Authors:  J Maisel; E M Scolnick; P Duesberg
Journal:  J Virol       Date:  1975-09       Impact factor: 5.103

2.  Molecular mechanisms involved in the differential expression of gag gene products by clonal isolates of a primate sarcoma virus.

Authors:  K C Robbins; H Okabe; S R Tronick; R V Gilden; S A Aaronson
Journal:  J Virol       Date:  1978-02       Impact factor: 5.103

3.  RNA associated with murine intracisternal type A particles codes for the main particle protein.

Authors:  B M Paterson; S Segal; K K Lueders; E L Kuff
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

4.  Rat sequences of the Kirsten and Harvey murine sarcoma virus genomes: nature, origin, and expression in rat tumor RNA.

Authors:  G R Anderson; K C Robbins
Journal:  J Virol       Date:  1976-02       Impact factor: 5.103

5.  Size of virus-specific RNA in B-34, a hamster tumor cell producing nucleic acids of type C viruses from three species.

Authors:  N Tsuchida; R V Gilden; M Hatanaka
Journal:  J Virol       Date:  1975-10       Impact factor: 5.103

6.  Conserved region of mammalian retrovirus RNA.

Authors:  R Kominami; M Hatanaka
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

7.  Nature and distribution of feline sarcoma virus nucleotide sequences.

Authors:  A E Frankel; J H Gilbert; K J Porzig; E M Scolnick; S A Aaronson
Journal:  J Virol       Date:  1979-06       Impact factor: 5.103

8.  Relationship between Moloney murine leukemia and sarcoma virus RNAs: purification and hybridization map of complementary DNAs from defined regions of Moloney murine sarcoma virus 124.

Authors:  D Dina; K Beemon
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

9.  Biochemical and immunological characterization of polyproteins coded for by the McDonough, Gardner-Arnstein, and Snyder-Theilen strains of feline sarcoma virus.

Authors:  M Barbacid; A V Lauver; S G Devare
Journal:  J Virol       Date:  1980-01       Impact factor: 5.103

10.  Tumorigenicity of Indian muntjac diploid cells by the proviral integration of sarcoma gene of a mouse retrovirus.

Authors:  M Hatanaka; R Klein
Journal:  J Exp Med       Date:  1979-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.